BTIG analyst Julian Harrison has maintained their bullish stance on LQDA stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Julian Harrison’s rating is based on Liquidia Technologies’ impressive financial performance and growth prospects. The company achieved non-GAAP profitability in its first full quarter since the launch of Yutrepia, surpassing previous expectations. Yutrepia’s revenue significantly exceeded consensus estimates, and its patient uptake and prescription rates have been notably strong, indicating robust market demand.
Moreover, Liquidia has secured financial agreements with major payors, enhancing access and potentially driving further growth. The company is also planning to expand Yutrepia’s market by initiating a clinical trial in IPF/PPF, which could broaden its total addressable market. Despite legal uncertainties surrounding the ‘327 patent trial, an IP trial attorney suggests a favorable outcome for Liquidia is likely, which could alleviate current market concerns. These factors collectively contribute to a positive outlook for Liquidia, justifying the Buy rating.
Harrison covers the Healthcare sector, focusing on stocks such as Cullinan Management, Oruka Therapeutics, and Nektar Therapeutics. According to TipRanks, Harrison has an average return of 32.3% and a 54.31% success rate on recommended stocks.
In another report released today, Raymond James also maintained a Buy rating on the stock with a $47.00 price target.